The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...

Progress in oncology, and more recently ophthalmology, led to the development of VEGF antagonists, three of which are now approved for the treatment of wet AMD. Recent discoveries in ophthalmology ...

Incorporate omega-3s into your diet: Foods like fish have been shown to reduce the risk of macular degeneration. Don’t forget to add a handful of walnuts to your meals as they’re also packed with ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This ...

The success of VEGF antagonists in wet AMD (Table 1) has confirmed the value of targeting angiogenesis in CNV lesions and has led to the development of novel anti-angiogenics, such as dual VEGF ...

When ophthalmologists see leaked fluid in the eye of someone with AMD, they can prescribe drugs such as ranibizumab that bind to vascular endothelial growth factor (VEGF) and inhibit blood-vessel ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth ...

Kodiak Sciences Inc. , today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day ...

Clearside Biomedical (CLSD) announced that presentations on the Company’s lead clinical program, CLS-AX in neovascular age-related macular ...